19 citations
,
August 2023 in “Journal of Dermatological Treatment” Abrocitinib may effectively treat stubborn alopecia universalis.
65 citations
,
October 2015 in “Acta Biomaterialia” The nano-carrier makes etoposide safer and more effective against lung cancer.
November 2025 in “Journal of Investigative Dermatology” 3 citations
,
November 2024 in “Viruses” Cepharanthine may help treat Equid herpesvirus type 8 by reducing oxidative stress.
6 citations
,
April 2022 in “Biomedicine & pharmacotherapy” Using three different drugs together may better treat eye diseases like glaucoma and macular degeneration.
1 citations
,
March 2011 in “Hospital Pharmacy” Various medications and vaccines can cause serious side effects.
January 2025 in “Geneesmiddelenbulletin” Baricitinib is effective and safe for treating severe alopecia areata with ongoing use.
September 2019 in “Journal of Investigative Dermatology” Abrocitinib at 100 mg and 200 mg daily may significantly improve moderate-to-severe atopic dermatitis in patients 12 years and older.
April 2011 in “Reactions Weekly”
2 citations
,
April 2023 in “Expert Review of Clinical Immunology” Baricitinib is effective as a treatment for severe hair loss.
January 2013 in “Biology of blood and marrow transplantation” Rapamycin increased survival in mice with severe chronic graft-versus-host disease by expanding regulatory T cells.
March 2026 in “Journal of Translational Autoimmunity” Ruxolitinib helps regrow hair in alopecia areata by blocking inflammation, reducing stress, and controlling cell death.
50 citations
,
July 2021 in “Nature Communications” The drug enzalutamide may reduce the ability of the virus causing COVID-19 to enter lung cells.
2 citations
,
May 2023 in “Journal of Immunotherapy” Sintilimab treatment caused hair loss but led to complete tumor remission.
18 citations
,
July 2008 in “Current Oncology Reports” EGFR cancer drugs often cause a rash, which can lead to distress and isolation, but may also improve outcomes for some cancer patients. Current treatments for the rash are limited, but a compound called menadione shows promise.
November 2025 in “Journal of Investigative Dermatology” Combining MMP-9 and JAK inhibitors can effectively prevent skin depigmentation in vitiligo.
May 2025 in “JEADV Clinical Practice” Tofacitinib and methotrexate successfully treated a woman's severe skin, joint, and hair loss issues.
1 citations
,
December 2012 in “Journal of dermatological science” Combining ficlatuzumab and gefitinib can cause severe scarring hair loss.
2 citations
,
February 2023 in “Actas Dermo-Sifiliográficas” Baricitinib effectively improved both atopic dermatitis and alopecia areata symptoms in a patient.
4 citations
,
January 1990 in “Journal of Dermatological Treatment” Stopping captopril resolved the skin and hair issues, suggesting it caused them.
5 citations
,
November 2012 in “Journal of Clinical Psychopharmacology” Valproic acid and isoniazid can interact, causing toxicity, so careful monitoring is needed.
1 citations
,
June 2013 in “Annals of the Rheumatic Diseases” Methotrexate plus prednisolone had the fewest serious side effects.
1 citations
,
March 2020 in “Poster presentations” SLE patients need careful diagnosis to distinguish infections from disease flares for proper treatment.
July 2025 in “Veterinary Parasitology Regional Studies and Reports” NexGard® and Frontline Combo® are both 100% effective at eliminating lice in dogs.
2 citations
,
July 2023 in “Journal of cosmetic dermatology” JAK inhibitors are more effective and safer for treating alopecia areata than dupilumab and apremilast.
September 2022 in “XXXIX Congresso Brasileiro de Reumatologia” Tofacitinib may effectively treat skin symptoms in difficult cases of dermatomyositis.
August 2013 in “Hospital Pharmacy” Certain medications can cause serious side effects, including skin reactions, stroke, muscle disorders, tongue swelling, hair loss in women, and liver failure.
January 2003 in “Hepatology”
25 citations
,
January 2011 in “Annals of Dermatology” Erlotinib can cause hair loss as a side effect.
February 2026 in “Oncology Reviews” Sacituzumab tirumotecan shows promise in treating breast cancer with manageable side effects.